Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • AZN H1 2025 revenue grew 11% YoY to GBP 28,045 million, with double-digit gains in Oncology and BioPharmaceuticals.
  • AstraZeneca reported 17% YoY growth in Core EPS to GBP 4.66 and 13% rise in Core operating profit.
  • AstraZeneca announced a GBP 50 billion investment in US manufacturing and R&D through 2030, including a new Virginia facility.

AstraZeneca plc (LON:AZN) is a global biopharmaceutical company headquartered in Cambridge, UK. The company focuses on the discovery, development, and commercialisation of prescription medicines, with a portfolio spanning Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism and Respiratory & Immunology), and Rare Disease. Its operations span more than 100 countries, with significant R&D and manufacturing capabilities.

For the six months ended 30 June 2025, AstraZeneca reported a Total Revenue increase of 11% year-on-year (at constant exchange rates) to GBP 28,045 million. Growth was supported by continued expansion in Oncology and BioPharmaceuticals across all major regions. Product Revenue growth was broad-based geographically and segmentally. Core Operating Profit rose by 13%, while Core Earnings Per Share (EPS) grew by 17% to GBP 4.66. The interim dividend increased by 3% to GBP 1.03 per share. The company delivered 12 positive Phase III readouts and received 19 regulatory approvals across key global markets during the period.

AstraZeneca also confirmed changes to financial reporting introduced in FY2025. The new Gross Margin metric now reflects a comprehensive view of all revenue categories, encompassing Product Sales, Alliance Revenue, and Collaboration Revenue. Additionally, the new ‘Product Revenue’ subtotal aggregates Product Sales and Alliance Revenue, reflecting changes in revenue mix. AstraZeneca reaffirmed its full-year 2025 guidance at constant exchange rates (CER), expecting Total Revenue to rise by a high single-digit percentage and Core EPS to grow by a low double-digit percentage. The Core tax rate is projected to remain between 18% and 22%.

In June 2025, AstraZeneca entered a strategic R&D collaboration with China-based CSPC Pharmaceutical Group. The agreement targets early-stage discovery across chronic diseases using AI-driven drug discovery platforms. CSPC received an upfront payment of GBP 110 million and stands to gain up to GBP 5.2 billion in milestones and royalties. In May, AstraZeneca acquired EsoBiotec, a cell therapy developer with a proprietary ENaBL platform. The deal included an upfront payment of GBP 403 million, with potential contingent consideration of up to GBP 575 million. This acquisition enhances AstraZeneca’s capabilities in oncology and immune-mediated therapies.

Most notably, AstraZeneca committed to a GBP 50 billion investment in the United States by 2030. This includes its largest-ever manufacturing investment planned for Virginia to support the production of next-generation metabolic and weight-management drugs, including oral GLP-1 and other pipeline therapies. The facility will incorporate AI, automation, and data analytics for efficient operations. AstraZeneca revised its sustainability strategy in H1FY25, aligning its business growth goals with commitments to societal and planetary health. The update underscores the company’s aim to address global health challenges through environmentally conscious practices. Despite potential foreign exchange risks, the company anticipates FY25 revenue and Core EPS growth in line with its CER guidance if exchange rates remain stable in H2. AstraZeneca is scheduled to release its Q3 and 9MFY25 results on 6 November 2025.

AZN shares were trading 1.19 % higher at GBX 10,918.00 per share as on 29 July 2025.